Reference range and short- and long-term biological variation of interleukin (IL)-6, IL-17A and tissue necrosis factor-alpha using high sensitivity assays

Cytokine

Volumn 64, Issue 3, 2013, Pages 660-665

  Todd, John ^a   Simpson, Peter ^a   Estis, Joel ^a   Torres, Victoria ^a   Wub, Alan H B ^b  

^a SINGULEX INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological variability; Interleukin; Tissue necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BIOLOGICAL VARIATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; VALIDATION PROCESS;

ERENNA;

ANALYTICAL, INTRA-ASSAY AND INTER-ASSAY COEFFICIENT OF VARIANCE, RESPECTIVELY, LOD, LIMIT OF DETECTION; BIOLOGICAL VARIABILITY; CLIA; CLINICAL LABORATORY IMPROVEMENT AMENDMENTS; CV(A), CV(I), CV(G); EDTA; ETHYLENEDIAMINETETRAACETIC ACID; HEART FAILURE; HF; HIGH-SENSITIVITY C-REACTIVE PROTEIN; HS-CRP; ICC; IL; INTERLEUKIN; INTRA-CLASS CORRELATION COEFFICIENT; LAB DEVELOPED TEST; LDT; LLOQ; LOWER LIMIT OF QUANTITATION; NEW YORK HEART ASSOCIATION; NYHA; TISSUE NECROSIS FACTOR; TISSUE NECROSIS FACTOR, CVD, CARDIOVASCULAR DISEASE; TNF-Α;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; IMMUNOASSAY; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MIDDLE AGED; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84886953166     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.09.018     Document Type: Article

References (39)

1. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
2. Mauriello A., Sangiorgi G., Fratoni S., et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005, 45:1585-1593.
3. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
4. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
5. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
6. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
7. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:668-674.
8. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
9. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5:e78.
10. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94:874-877.
11. Ikonomidis I., Athanassopoulos G., Lekakis J., et al. Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study. Circulation 2005, 112:3272-3279.
12. Kavsak P.A., Ko D.T., Newman A.M., et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and n-terminal pro-brain natriuretic peptide. Clin Chem 2007, 53:2112-2118.
13. Raaz-Schrauder D., Klinghammer L., et al. Association of systemic inflammation markers with the presence and extent of coronary artery calcification. Cytokine 2012, 57:251-257.
14. McDermott M.M., Liu K., Ferrucci L., et al. Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease. Am J Cardiol 2011, 107:1392-1398.
15. Kalogeropoulos A., Georgiopoulou V., Psaty B.M., et al. Inflammatory markers and incident heart failure risk in older adults: the health abc (health, aging, and body composition) study. J Am Coll Cardiol 2010, 55:2129-2137.
16. Luc G., Bard J.M., Juhan-Vague I., et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the prime study. Arterioscler Thromb Vasc Biol 2003, 23:1255-1261.
17. Kablak-Ziembicka A., Przewlocki T., Sokolowski A., Tracz W., Podolec P. Carotid intima-media thickness, hs-CRP and TNF-alpha are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis 2011, 214:185-190.
18. Khan D.A., Ansari W.M., Khan F.A. Pro/anti-inflammatory cytokines in the pathogenesis of premature coronary artery disease. J Interf Cytokine Res 2011, 31:561-567.
19. Dunlay S.M., Weston S.A., Redfield M.M., Killian J.M., Roger V.L. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008, 118:625-631.
20. Zhu F., Wang Q., Guo C.W., et al. Il-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin Immunol 2011, 141:152-160.
21. de Boer O.J., van der Meer J.J., Teeling P., et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010, 220:499-508.
22. Erbel C., Dengler T.J., Wangler S., et al. Expression of IL-17a in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011, 106:125-134.
23. Ikonomidis I., Papadimitriou C., Vamvakou G., et al. Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. Growth Factors 2008, 26:117-124.
24. Folsom A.R., Chambless L.E., Ballantyne C.M., et al. An assessment of incremental coronary risk prediction using c-reactive protein and other novel risk markers: The atherosclerosis risk in communities study. Arch Int Med 2006, 166:1368-1373.
25. Ho G.Y., Xue X.N., Burk R.D., Kaplan R.C., Cornell E., Cushman M. Variability of serum levels of tumor necrosis factor-alpha, interleukin 6, and soluble interleukin 6 receptor over 2 years in young women. Cytokine 2005, 30:1-6.
26. Karakas M., Baumert J., Greven S., Ruckerl R., Peters A., Koenig W. Reproducibility in serial c-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: Results from the airgene study. Clin Chem 2010, 56:861-864.
27. Dibbs Z., Thornby J., White B.G., Mann D.L. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: Implications for clinical trials. J Am Coll Cardiol 1999, 33:1935-1942.
28. Wu A.H., Akhigbe P., Wians F. Long-term biological variation in cardiac troponin I. Clin Biochem 2012, 45:714-716.
29. Todd J., Freese B., Lu A., Held D., Morey J., Livingston R., et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 2007, 53:1990-1995.
30. Fraser C.G. Biological variation: from principles to practice 2001, Am Assoc Clin Chem Press, Washington (DC).
31. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997, 43:52-58.
32. Clark G.H., Fraser C.G. Biological variation of acute phase proteins. Ann Clin Biochem 1993, 30:373-376.
33. Cho L.W., Jayagopal V., Kilpatrick E.S., Atkin S.L. The biological varation of C-reactive protein in polycystic ovarian syndrome. Clin Chem 2005, 51:1905-1907.
34. Cava F., Gonzalez C., Pascual M., Navajo A., Gonzalez-Buitrago J.M. Biological variation of interleukin6 (IL-6) and soluble interleukin 2 receptor (sIL2R) in serum of healthy individuals. Cytokine 2000, 12:1423-1425.
35. Cardinal J., Pretorius C.J., Ungerer J.P.J. Biological and diurnal variation in glucocorticoid sensitivity detected with a sensitive in vitro dexamethasone suppression of cytokine production assay. J Clin Endocrinol Metab 2010, 95:3657-3663.
36. Gonzalez C., Cava F., Ayllon A., Guevara P., Navajo J.A., Gonzalez-Buitrago J.M. Biological variation of interleukin-1 beta, interleukin-8 and tumor necrosis factor-alpha in serum of healthy individuals. Clin Chem Lab Med 2001, 39:836-841.
37. Navarro S.L., Brasky T.M., Schwarz Y., et al. Reliability of serum biomarkers of inflammation from repeated mesures in healthy individuals. Cancer Epidemiol Biom Prev 2012, 21:1167-1170.
38. Smith E., Prasad K.M.R., Butcher M., Dobrian A., Kolls J.K., Ley K., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
39. Erbel C., Dengler T.J., Wangler S., et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011, 106:125-134.